More than 90% of CML cases are driven by the BCR-ABL fusion, which is uniquely sensitive to tyrosine kinase inhibitors (TKI) such as imatinib. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.